Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
DMAC vs CAPR: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
DMAC Captures Overall Composite Edge (46.3 HOLD vs 28.0 SELL), While CAPR Leads 4–1 on Growth & Valuation Pillars
DMAC Overall Winner
6-Pillar Tally: DMAC 1 – 4 CAPR (1 Tie)
Matrix Metrics: DMAC 4 – 4 CAPR
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Capricor Therapeutics Inc (CAPR) on higher Unified Composite conviction (46.3/100 HOLD vs. 28.0/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow), while CAPR wins 4–1 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus CAPR at $8.47 (78.7x Forward P/E, 0.0% operating margin).
- Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. CAPR 28.0/100 SELL) and 1.74β · 98% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About DMAC vs CAPR
DMAC
Head-to-Head Winner
DiaMedica Therapeutics Inc. Common Stock
$8.41
-4.27% 1D
Market Cap
$503.1M
TTM Revenue
N/A
Forward P/E
N/M
Beta / 30D Vol
1.74β · 98% Vol
Unified Composite Score
46.3
HOLD
Tech 30.0
Fund 51.0
Flow 65.0
Mom 60.0
Weinstein Technical Phase
Neutral · Hold
CAPR
Capricor Therapeutics Inc
$8.47
-11.12% 1D
Market Cap
$595.4M
TTM Revenue
$11M
Forward P/E
78.7x
Beta / 30D Vol
1.52β · 152% Vol
Unified Composite Score
28.0
SELL
Tech 50.0
Fund 37.0
Flow 68.0
Mom 50.0
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (DMAC 1 – 4 CAPR)
1. Valuation Multiples
CAPR
Forward P/E
N/M
78.7x
Trailing P/E
N/M
78.7x
PEG Ratio
N/M
0.38x
EV / Revenue
N/M
57.8x
2. Growth & Scale
CAPR
Revenue Growth (YoY)
+0.0%
-7.9%
Earnings Growth (YoY)
+0.0%
+0.0%
TTM Revenue (USD)
N/A
$11M
Market Cap
$503.1M
$595.4M
3. Profitability & Quality
CAPR
Gross Margin
N/A
N/A
Operating Margin
0.0%
0.0%
Net Profit Margin
0.0%
0.0%
Return on Equity (ROE)
-114.6%
-100.5%
4. Balance Sheet & Cash Flow
DMAC
Cash Generation (TTM)
-$32M
-$146M
Cash Flow Margin
N/A
N/A
Net Cash / Leverage
$4.9M Net Cash
$48M Net Debt (0.44x D/E)
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
CAPR
Options Structure Phase
SURGE
CONSOLIDATION
Current IV / %ile
106.3% (14th %ile)
637.1% (89th %ile)
Put/Call OI Skew
N/A
1.57x (Put-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Neutral
ACCUMULATION · Markup
6. R&D & Supply-Chain Moat
Tie
OpEx & R&D Intensity
N/A
N/A
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Biotechnology Operator
Biotechnology Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: DMAC (4) vs CAPR (4)| Institutional Metric | DMAC | CAPR | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $503.1M | $595.4M | CAPR | |
| Trailing P/E Ratio | N/M | 78.7x | CAPR | |
| Forward P/E Ratio | N/M | 78.7x | CAPR | |
| Revenue Growth (YoY) | +0.0% | -7.9% | DMAC | |
| Operating Margin (TTM) | 0.0% | 0.0% | Tie | |
| Net Profit Margin | 0.0% | 0.0% | Tie | |
| Return on Equity (ROE) | -114.6% | -100.5% | CAPR | |
| 52-Week Range Position | 55% ($5–$11) | 15% ($3–$40) | DMAC | |
| Beta / 30D Volatility | 1.74β · 98% Vol | 1.52β · 152% Vol | DMAC | |
| Unified Institutional Score | 46.3 / 100 (HOLD) | 28.0 / 100 (SELL) | DMAC | |
| Trailing 12M Revenue (USD) | N/A | $11M | Scale | |
| Gross Profit Margin (TTM) | N/A | N/A | Quality | |
| PEG Ratio & EV / Revenue | N/M PEG · N/M EV/Rev | 0.38x PEG · 57.8x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | -$32M ($4.9M Net Cash) | -$146M ($48M Net Debt (0.44x D/E)) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
CAPR +15.07 pp
3M Horizon
DMAC +7.68 pp
6M Horizon
DMAC +109.44 pp
1Y Horizon
DMAC +8.47 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | DMAC Revenue | CAPR Revenue | DMAC Op. Margin | CAPR Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2017 | N/A | $0M | N/A | -482.4% | CAPR |
| FY2018 | $0M | $0M | -1352.2% | -917.0% | CAPR |
| FY2019 | N/A | $0M | N/A | -769.5% | CAPR |
| FY2020 | N/A | $0M | N/A | -4412.6% | CAPR |
| FY2021 | N/A | $0M | N/A | -8549.9% | CAPR |
| FY2022 | N/A | $0M | N/A | -1163.9% | CAPR |
| FY2023 | N/A | $30M | N/A | -95.6% | CAPR |
| FY2024 | N/A | $20M | N/A | -191.1% | CAPR |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
DMAC
SURGE
Current IV
106.3%
IV Percentile
14th %ile
Put/Call OI Skew
N/A
IV Regime
Compressed (<25th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact DMAC Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
CAPR
CONSOLIDATION
Current IV
637.1%
IV Percentile
89th %ile
Put/Call OI Skew
1.57x (Put-Skewed)
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
ACCUMULATION
Exact CAPR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
DMAC Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
CAPR Moat Profile
Cyclical / Execution-Driven Positioning
Biotechnology Operator
OpEx & R&D Reinvestment
N/A
90D Engineering Disclosures
0 Published
Investor FAQ DMAC vs CAPR Key Questions & Quantitative Answers
As of Nov 16, 2026, DiaMedica Therapeutics Inc. (DMAC) captures the overall head-to-head institutional edge over Capricor Therapeutics Inc (CAPR) on higher Unified Composite conviction (46.3/100 HOLD vs. 28.0/100 SELL) after splitting the core matrix 4–4 (led by Balance Sheet & Cash Flow), while CAPR wins 4–1 across the 6-pillar growth and valuation breakdown. DMAC trades at $8.41 (N/M Forward P/E, 0.0% operating margin) versus CAPR at $8.47 (78.7x Forward P/E, 0.0% operating margin). Growth vs. Quality Trade-Off: DMAC earns the overall head-to-head edge with a stronger Unified Composite Score (46.3/100 HOLD vs. CAPR 28.0/100 SELL) and 1.74β · 98% Vol risk profile, whereas CAPR leads top-line expansion (-7.9% YoY revenue growth, 0.38x PEG, and 4 of 6 institutional pillars) for higher-beta growth mandates.
CAPR leads the Growth & Scale pillar: DMAC posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with CAPR at -7.9% YoY revenue growth and +0.0% YoY earnings growth on $11M TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2017 to FY2024), DMAC cumulative revenue shifted N/A while CAPR shifted -33.3%. In operating R&D and SG&A reinvestment, DMAC deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CAPR.
CAPR screens cheaper on headline valuation multiples. DMAC trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas CAPR trades at 78.7x Forward P/E, 78.7x Trailing P/E, 0.38x PEG, and 57.8x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against DMAC (-114.6% ROE) versus CAPR (-100.5% ROE) capital efficiency.
In options market volatility and institutional positioning, DMAC carries 106.3% implied volatility (14th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in a SURGE options structure phase (1.74β · 98% Vol realized risk). By comparison, CAPR carries 637.1% implied volatility (89th %ile, Extreme (>80th %ile)), a 1.57x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.52β · 152% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
CAPR vs DMAC · Reverse Pair
DMAC vs TRVI
· Sector Peer
DMAC vs VRCA
· Sector Peer
DMAC vs FENC
· Sector Peer
CAPR vs MBRX
· Sector Peer
CAPR vs AKTX
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem